Key success factors behind high-performing spin-offs, including team, science, funding strategy and execution. What to take into account in the early stages to move fast, de-risk projects and build strong foundations for growth. Insights and lessons learned from real cases and different stakeholder perspectives.
- Agnés Arbat (Oxolife) - Spanish biotech founder
- Gustavo Fuster (Hoffmann Eitle) - IP lawyer
- Etienne Drouet (IQVIA) – CRO (Regulatory and Clinical)
- Marcos Simón (CIC Biomagune) – Head of TTO
